Given the critical role of mutant p53 stability in its oncogenic activity (Freed-Pastor and Prives, 2012; Muller et al., 2014; Alexandrova et al., 2015), these findings indicate that the PIPKIα and PIPKIα–p53–PI(4,5)P–sHSP complexes might serve as therapeutic targets for cancer. The gene discussed is TP53; the disease is cancer.